Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 10c, Raises FY EPS Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. FIX
9. TSCO
10. BE

Go back to Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 10c, Raises FY EPS Guidance

Jazz Pharmaceuticals (JAZZ) Price Target Raised to $190 at UBS

November 5, 2014 9:11 AM EST

UBS maintained a Buy rating on Jazz Pharmaceuticals (NASDAQ: JAZZ) and raised its price target to $190.00 (from $180.00). The change follows Q3 results.

Analyst Marc Goodman said, "It was another solid quarter, and Jazz has clearly demonstrated that 1Q was an anomaly. Xyrem... More